Satisfying the needs of politicians inside the World Health Organization is not going to fight AIDS infection.

There is a second world of drug research, a world in which patents do not exist and for-profit research is permanently moribund. Its history should stop "reformers" in their tracks.

Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics, which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer.

Indian bureaucrats and politicians must overcome short-term thinking and improve India's IP systems by ensuring that deserving products receive patents and making sure trademarks are enforced. Only then will India develop a true innovation economy.

Permitting slightly higher drug prices today will guarantee incentives for innovation and development tomorrow.

India is on the brink of finalizing a free trade agreement with the European Union. Yet even as the deal gets close, one area remains hotly contested: protection for intellectual property (IP). Controversy mounts over "data exclusivity" for pharmaceuticals.

As regulators seek to weigh the potential benefits and risks of a new medicine, my own observation is that they tend to be both tentative and ultra-paternalistic.

Controversies surrounding pharmaceutical patents and trade rules in the WTO

Pharmaceutical patents, drug prices, and parallel imports of drugs from lower-income to higher-income nations have been at the center of some of the most contentious debates in the run-up to Cancun. This panel will analyze the positions of the various protagonists...